Sartorius Stedim Biotech records strong growth in 2025

Sartorius Stedim Biotech, a leader in biotechnology manufacturing, announces significant growth in 2025. Preliminary unaudited revenue reached €2,967 million, representing a 9.6% increase at constant exchange rates. With current EBITDA of €914 million and a margin of 30.8%, the company recorded net income of €266 million.

Growth was primarily driven by recurring activities related to high-margin consumables. Revenues in the EMEA, Americas, and Asia-Pacific regions all showed growth, with respective increases of 7.3%, 11.8%, and 10.7% at constant exchange rates.

For 2026, Sartorius Stedim Biotech anticipates continued profitable growth, focusing on innovation and operational excellence, despite macroeconomic and geopolitical uncertainties. The company projects revenue growth of 6% to 10% at constant exchange rates.